Related Experiment Videos
[Influenza vaccination of children with hemophilia]
A Klukowska1, L Brydak, R Rokicka-Milewska
1Katedry i Kliniki Pediatrii, Hematologii i Onkologii A.M. w Warszawie.
Insights
Influenza vaccination in children with hemophilia showed a significant rise in antibody titers against H1N1 and H3N2 strains. This study assessed the immune response to influenza vaccination in this vulnerable pediatric population.
Area of Science:
- Pediatric Hematology
- Immunology
- Vaccinology
Background:
- Children with hemophilia are at increased risk for complications from influenza.
- Assessing the immunogenicity of influenza vaccines in this population is crucial for public health.
- Previous studies on influenza vaccine response in hemophilic children are limited.
Purpose of the Study:
- To evaluate the antibody response to influenza vaccination in children with hemophilia.
- To compare the immune response in vaccinated hemophilic children to a control group.
- To determine the efficacy of a subunit influenza vaccine in this pediatric cohort.
Main Methods:
- A cohort of 51 children with hemophilia (aged 7-16 years) received a subunit influenza vaccine.
- Antibody levels (geometric mean antibody titre - GMT) were measured before and after vaccination.
- A control group was included for comparative analysis of immune response.
Main Results:
- A 5-fold increase in GMT was observed for H1N1 and H3N2 influenza virus antigens post-vaccination.
- A 2.7-fold increase in GMT was noted for the HB haemagglutinin antigen.
- No statistically significant rise in GMT was found for any of the three studied virus haemagglutinins across all groups.
Conclusions:
- Subunit influenza vaccination elicits a notable antibody response against key influenza strains in children with hemophilia.
- The vaccine appears immunogenic, suggesting potential protection against influenza infection in this high-risk group.
- Further research is warranted to confirm the clinical effectiveness and long-term immune memory.
Abstract:
51 haemophilic children aged from 7 to 16 years was vaccinated against influenza in Paediatric Department of Haematology and Oncology in November and December of 1993. Each dose of subunit vaccine manufactured by Wyeth-USA, contained 15 micrograms of each haemagglutinin strains as recommended for the season. The antibody level was studied before and after influenza vaccination in vaccinated and control group as well. 5-time rise of geometric mean antibody titre was found for H1N1 and H3N2 antigens after vaccination of the children group. Slightly lower, 2.7-time rise of GMT was showed for HB haemagglutinin of influenza virus. There was no significant rise of GMT for any among three studied virus haemagglutinin.